Mannose

DUBLIN--( BUSINESS WIRE )--The "D-Mannose - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for D-Mannose was estimated at US$830.8 Million in 2023 and is projected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growing awareness of the benefits of natural and non-prescription treatments has contributed to the popularity of D-Mannose among health-conscious consumers. It is frequently recommended as a preventive solution, especially for individuals with recurrent UTIs. With an increasing preference for natural and functional health products, D-Mannose is becoming a staple in the dietary supplement market. What Factors Are Driving the Growth of the D-Mannose Market? The growth in the D-Mannose market is driven by several factors, including the increasing preference for natural health products, rising consumer awareness about urinary health, and scientific research validating its benefits. The trend towards self-care and preventive health management has led consumers to seek non-pharmaceutical alternatives, boosting D-Mannose sales as a trusted and effective option. The rise of e-commerce platforms has further facilitated access to these products, making them available to a global audience. In addition, the focus on women's health and the emphasis on solutions for recurrent UTIs have propelled the demand for D-Mannose. Innovation in product formulations, such as incorporating D-Mannose with probiotics or other natural ingredients, also contributes to market growth by appealing to health-conscious consumers seeking holistic and multifunctional supplements. How Are Scientific Studies Supporting the Growth of the D-Mannose Market? The scientific validation of D-Mannose's efficacy in preventing UTIs has played a significant role in the expansion of its market. Clinical studies have demonstrated that D-Mannose can significantly reduce the incidence of recurrent UTIs without the adverse effects associated with long-term antibiotic use. These findings have led healthcare professionals and naturopaths to recommend D-Mannose as a preventive measure or supplementary treatment for urinary health. Furthermore, research exploring its additional benefits, such as improving gut health and supporting overall immune function, is expanding its application scope beyond urinary care. This scientific backing not only boosts consumer confidence but also attracts investment and innovation in the development of D-Mannose products, including powders, capsules, and beverages. Where Are D-Mannose Products Being Utilized and Sold? D-Mannose products are primarily sold through health stores, pharmacies, and online retail platforms specializing in dietary supplements. The convenience of e-commerce has allowed consumers to access D-Mannose products easily, contributing to its widespread availability and use. Apart from standalone supplements, D-Mannose is also incorporated into combination products that address urinary health, such as cranberry supplements and probiotics. This multifunctional approach appeals to consumers seeking comprehensive wellness solutions. Additionally, healthcare professionals and clinics focusing on natural medicine and women's health often recommend and distribute D-Mannose, increasing its penetration into medical and wellness practices. The growth in demand is not limited to developed markets; emerging economies are also witnessing increased adoption as awareness of natural and preventive healthcare options rises. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players in the Global D-Mannose Market such as Atrium Innovations, Inc., Biotech Pharmacal, Inc., Dow, Inc., DuPont de Nemours, Inc., Hanseler AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the D-Mannose Capsule segment, which is expected to reach US$592.9 Million by 2030 with a CAGR of a 4.1%. The D-Mannose Tablet segment is also set to grow at 3.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $223.7 Million in 2023, and China, forecasted to grow at an impressive 5.9% CAGR to reach $218.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Attributes: Report Attribute Details No. of Pages 246 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $830.8 Million Forecasted Market Value (USD) by 2030 $1100 Million Compound Annual Growth Rate 3.7% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of COVID-19 and a Looming Global Recession D-Mannose - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Urinary Tract Infections (UTIs) Boosting Demand for D-Mannose Growing Consumer Preference for Natural and Plant-Based Supplements Increasing Awareness About the Health Benefits of D-Mannose in Preventive Healthcare Development of D-Mannose-Based Products for Enhanced Bioavailability Expansion of the Functional Foods and Dietary Supplements Market Supporting Growth Increasing Focus on Women's Health and UTI Prevention Driving Product Adoption Rising Popularity of D-Mannose as an Alternative to Antibiotics Growth in Online Retail Channels Expanding Accessibility of D-Mannose Supplements Demand for Organic and Non-GMO Supplements Fueling Market Expansion Expansion of Clinical Studies Validating the Efficacy of D-Mannose in UTI Treatment Innovations in Product Formulations Such as Capsules, Powders, and Gummies Increase in Direct-to-Consumer Marketing Strategies Expanding Market Reach FOCUS ON SELECT PLAYERS: Some of the 46 companies featured in this Global D-Mannose report include Atrium Innovations, Inc. Biotech Pharmacal, Inc. Dow, Inc. DuPont de Nemours, Inc. Hanseler AG Jarrow Formulas, Inc. Kyowa Hakko Kirin Co., Ltd. Now Health Group, Inc. Nutraceutical Corporation Pfanstiehl, Inc. VWR International LLC For more information about this report visit https://www.researchandmarkets.com/r/8v07au About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Avalo only has eyes for the drug and won’t be taking on any of Almata’s staff. Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). The anti-IL-1β mAb, dubbed AVTX-009, has its origins at Eli Lilly. Avalo CEO Garry Neil, M.D., said the antibody has a “high probability of success for the treatment of HS as evidenced by recent data readouts validating inhibition of IL-1β in this disease.” “We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing,” Neil added in a post-market release yesterday. Avalo will make AVTX-009 its lead asset, ahead of quisovalimab, an anti-LIGHT mAb in phase 2 development for ulcerative colitis, and AVTX-008, a BTLA agonist fusion protein in preclinical development. The biotech expects to read out topline results from a phase 2 study of AVTX-009 in HS in 2026, and also alluded to plans to evaluate the antibody in another chronic inflammatory indication. To get its hands on the drug, Avalo is paying out $15 million in stock and a further $7.5 million in cash to acquire Almata outright. Almata’s former stockholders are also in line for a $5 million payout when the first patient is dosed in the phase 2 trial and $15 million if a patient is dosed in a phase 3 trial. The acquisition of privately-held Almata marks the end of a short life for the biotech, which was set up in April 2023 with the aim of identifying and licensing AVTX-009. While Almata will become a subsidiary of Avalo, the new owner only has eyes for the drug itself and won’t be taking on any of Almata’s staff. "We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with inflammatory diseases,” Almata’s now-former CEO Patrick Crutcher said in the release. “AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio team to this mission,” Crutcher added. “We look forward to the advancement of AVTX-009 into a phase 2 trial in HS under Dr. Neil’s stewardship.” Avalo hasn’t had an easy time in recent years. Back in 2022, the company was forced to cut down its pipeline and lost a chunk of its C-suite. Only last summer, the biotech had to work through a default with creditors before selling off its rare disease meds AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics. But with $35 million in debt eliminated and potentially up to $45 million in milestone payments to come from the offloaded AVTX-800 series, Avalo ended 2023 in a better place, even if it only had $10 million in the bank. Luckily, Avalo’s money worries have now been eased, with the company also announcing yesterday a $185 million raise via a private placement of various types of stock. The funding is expected to fuel the phase 2 trial of AVTX-009 and beyond into 2027. Investors appeared relieved at Avalo’s change in fortunes, sending the biotech’s stock rocketing over 330% in pre-marketing trading this morning to $20.50 from a Wednesday closing price of $4.75.